Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection

Cancer

Volumn 86, Issue 7, 1999, Pages 1143-1150

  Lee, Chuan Mo ^a   Lu, Sheng Nan ^a   Changchien, Chi Sin ^a   Yeh, Chau Ting ^a   Hsu, Tsung Teng ^a   Tang, Jui Hsiang ^a   Wang, Jing Houng ^a,b   Lin, Deng Yn ^a   Chen, Chao Long ^a   Chen, Wei Jen ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b God's Help Hospital   (Taiwan)

Author keywords

Geographic variation; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; FEMALE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS CARCINOGENESIS;

AGE FACTORS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C ANTIBODIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; SEX FACTORS; TAIWAN;

EID: 0033214863     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1143::AID-CNCR7>3.0.CO;2-Z     Document Type: Article

References (55)

1. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiological consideration. Hepatology 1982;2 (Suppl):21-6.
2. Linsell A. Primary liver cancer: global epidemiology and main aetiological factors. Ann Acad Med Singapore 1984;13: 185-9.
3. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
4. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990;87:6547-9.
5. Dazza MC, Meneses LV, Girard PM, Astagneau P, Villaroel C, Delaporte E, et al. Absence of a relationship between antibodies to hepatitis C virus and hepatocellular carcinoma in Mozambique. Am J Trop Med Hyg 1993;48:237-42.
6. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-6.
7. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991;67:429-33.
8. Hadziyannis SJ, Giannoulis G, Hadziyannis E, Kaklamani E, Alexopoulou A, Dourakis S, et al. Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. J Hepatol 1993;17:S72-7.
9. Al Karawi MA, Shariq S, el Shiekh Mohamed AR, Saeed AA, Ahmed AM. Hepatitis C virus infection in chronic liver disease and hepatocellular carcinoma in Saudi Arabia. J Gastroenterol Hepatol 1992;7:237-9.
10. Chang WY, Wang LY, Chuang WL, Chen SC, Lu SN, You SL. Anti-HCV antibody in Chinese cirrhotic patients with or without hepatocellular carcinoma: relation to multitransfusion. J Gastroenterol Hepatol 1992;7:128-31.
11. Di Bisceglie AM, Order SE, Klein JL, Waggoner JG, Sjogren MH, Kuo G, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991;86:335-8.
12. Ramesh R, Munshi A, Panda SK. Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma patients in India. J Gastroenterol Hepatol 1992;7: 393-5.
13. Pramoolsinap C, Sumalnop K, Busagorn N, Kurathong S. Prevalence of outcomes of HBV and anti-HCV seropositive patients with chronic liver disease and hepatocellular carcinoma. Southeast Asian J Trop Med Public Health 1992;23: 6-11.
14. Kiyosawa K, Tanaka E, Sodeyama T, Yoshizawa K, Yabu K, Furuta K, et al. Transmission of hepatitis C in an isolated area in Japan: community-acquired infection. Gastroenterology 1994;106:1596-602.
15. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994;51:563-7.
16. Louis FJ, Mauber B, Le Hesran JY, Kemmegne J, Delaporte E, Louis JP. High prevalence of anti-hepatitis C virus antibodies in a Cameroon rural forest area. Trans R Soc Trop Med Hyg 1994;88:53-4.
17. Tong MJ, Sun SC, Schaeffer BT, Chang NK, Lo KJ, Peters RL. Hepatitis-associated antigen and hepatocellular carcinoma in Taiwan. Ann Intern Med 1971;75:687-91.
18. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990;162:871-22.
19. Liaw YF, Chien RN, Sheen IS, Lin DY, Lin HH, Chu CM. Hepatitis C virus infection in patients with chronic liver disease in an endemic area for hepatitis B virus infection. Gastroenterol Jpn 1991;26 (Suppl 3):167-9.
20. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, et al. Different viral etiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 1997;12:547-50.
21. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between B- and C-infection in Japan. Hepatology 1995;22:1027-33.
22. Sung JL, Chen DS. Maternal transmission of hepatitis B surface antigen in patients with hepatocellular carcinoma in Taiwan. Scand J Gastroenterol 1980;15:321-4.
23. Lee SD, Chan CY, Wang YJ, Wu JC, Lai KH, Tsai YT, et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991;13:830-3.
24. Sung JL, Wang TH, Yu JY. Clinical study on primary carcinoma of the liver in Taiwan. Am J Dig Dis 1967;12:1036-49.
25. Lai CL, Gregory PB, Wu PC, Lok AS, Wong KP, Ng MM. Hepatocellular carcinoma in Chinese males and females: possible causes for the male predominance. Cancer 1987;60: 1107-10.
26. Chen CJ, Liang KY, Chang AS, Chang YC, Lu SN, Liaw YF, et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991;13:398-406.
27. Kigosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;4(Pt 1):671-5.
28. Esteban JI, Esteban R, Viladomiu L, Lopez-Talavera JC, Gonzalez A, Hernandez JM, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2(8658):294-7.
29. Watanabe J, Minegishi K, Mitsumori T, Ishifuji M, Oguchi T, Ueda M, et al. Prevalence of anti-HCV antibody in blood donors in the Tokyo area. Vox Sang 1990;59:86-8.
30. Tibbs CJ, Palmer SJ, Coker R, Clark SK, Parsons GM, Hojvat S, et al. Prevalence of hepatitis C in tropical communities: the importance of confirmatory assays. J Med Virol 1991;34: 143-7.
31. al-Faleh FZ, Ayoola EA, al-Jeffry M, al-Rashed R, al-Mofarreh M, Arif M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study. Hepatology 1991;14:215-8.
32. Suou T, Ikuta Y, Hasegawa M, Kawasaki H. Prevalence of HCV antibodies in Yatsuka town of Simane prefecture, Japan [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 1992; 89:1173-8.
33. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14.
34. Alter MJ, Sampliner RE. Hepatitis C: and miles to go before we sleep. N Engl J Med 1989;321:1538-40.
35. Alter MJ. Inapparent transmission of hepatitis C: footprints in the sand. Hepatology 1991;14:389-91.
36. Perez-Romero M, Sanchez-Quijano A, Lissen E. Transmission of hepatitis C virus [letter]. Ann Intern Med 1990;113: 411.
37. Noguchi S, Sata M, Suzuki H, Mizokami M, Tanikawa K. Routes of transmission of hepatitis C in an endemic rural area of Japan: molecular epidemiologic study of hepatitis C virus infection. Scand J Infect Dis 1990;29:23-8.
38. Munro J, Briggs JD, McCruden EA. Detection of a cluster of hepatitis C infections in a renal transplant unit by analysis of sequence variation of the NS5a NS5a gene. J Infect Dis 1996;174:177-80.
39. Liaw YF, Tsai SL, Chang JJ, Sheen IS, Chien RN, Lin DY, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994;106:1048-53.
40. Sheen IS, Liaw YF, Lin DY, Chu CM. Role of hepatitis C and delta virus in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994;170:358-61.
41. Okuda K. Hepatocellular carcinomas associated with hepatitis B and C virus infections: are they any different? Hepatology 1995;22:1883-5.
42. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-9.
43. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-5.
44. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24: 141-7.
45. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-9.
46. Imai Y, Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-9.
47. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998;82:827-35.
48. Wang JH, Lu SN, Hsu CT. Hepatitis C is one major viral etiology of hepatocellular carcinoma in Chiayi and Yingling. J Intern Med Taiwan 1998;9:120-5.
49. Donahue JG, Munoz A, Ness PM, Brown DE Jr., Yawn DH, McAllister HA. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
50. Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of posttransfusion hepatitis. Lancet 1991;338:1040-1.
51. Gonzalez A, Esteban JI, Madoz P, Viladomiu L, Genesca J, Muniz E, et al. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial. Hepatology 1995;22: 439-45.
52. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
53. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105:507-12.
54. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
55. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.